| Autor: |
Uğur KÜÇÜK, Bahadır KIRILMAZ, Ertuğrul ERCAN |
| Jazyk: |
English<br />Turkish |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Namık Kemal Tıp Dergisi, Vol 10, Iss 2, Pp 175-180 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2587-0262 |
| DOI: |
10.4274/nkmj.galenos.2022.86548 |
| Popis: |
Aim:We aimed to investigate the relationship of serially measured pentraxin-3 (PTX3) levels with Gensini risk score and cardiovascular mortality in long-term follow-up in patients who underwent percutaneous coronary intervention (PCI) with the diagnosis of non-ST elevation myocardial infarction (NSTEMI) and stable angina pectoris (SAP).Materials and Methods:Our study was planned retrospectively, and the long-term cardiovascular mortality results of patients with NSTEMI and SAP, who underwent PCI, were evaluated. Our study consisted of two groups, including the study and the control groups. Eighteen patients with NSTEMI who underwent PCI were included in the study group, and 37 patients with a diagnosis of SAP were included in the control group. Blood samples were taken from all patients for PTX3 measurements at the time of admission, at the 8th and 24th hours. Gensini scores were calculated before PCI.Results:PTX3 levels measured at the eighth hour were found to be numerically and statistically significant in NSTEMI patients compared to SAP patients [13.37 (5.47-27.75) and 5 (3.83-12.42), p=0.006]. PTX3 values measured at the time of admission were found to be associated with Gensini score (r=0.299, p=0.026). PTX3 values measured at the eighth hour were found to be independent predictors of long-term cardiovascular mortality (Hazard ratio: 1.294, 95% confidence interval: 1024-1.653, p=0.039).Conclusion:PTX3 may be helpful in identifying individuals at high risk for cardiovascular mortality in the long term in NSTEMI patients. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
